Aviado · Research
Longevity Daily
Saturday, April 18, 2026
Listen
Today's Brief
Today's issue is about separating longevity signal from noise. Our must-read — from the New York Times — maps six common medications that may quietly protect against dementia, while a major review challenges the real-world impact of the heavily hyped Alzheimer's amyloid drugs. A landmark Nature Communications study (n=5,968) introduces a compelling new biomarker: oral microbiome aging scores that outperform conventional risk factors for mortality and heart attack prediction. Rounding out the issue, a first-of-its-kind clinical trial confirms that 150 minutes of weekly aerobic exercise measurably lowers cortisol and slows brain aging.
10 stories3 peer-reviewed2 trials
Cognitive Health & Neuroprotection
Six Common Medications That May Quietly Protect Against Dementia
Statins, blood pressure drugs, GLP-1 receptor agonists, flu vaccines, and a handful of other everyday medications have all been associated with reduced dementia risk — but the story is more complicated than it looks. Researchers caution that many of these correlations reflect 'healthy user bias': people who take their pills also see doctors regularly and follow health advice, making it hard to isolate the true drug effect. Still, the article synthesizes the most compelling mechanistic arguments for each medication class, making it a valuable reference for anyone managing long-term brain health. If you already take any of these drugs, the case for staying the course just got a bit stronger.
Read more →GLP-1 Drugs Show Promising Early Evidence for Parkinson's and Brain Protection
GLP-1 receptor agonists — the same drug class behind Ozempic and Wegovy — are showing neurological benefits well beyond blood sugar control. A double-blind, placebo-controlled trial (n=59) presented at the 2025 MDS Congress found significant effects on Parkinson's motor symptoms after 9 months (P=.001), and vascular risk reduction may provide an additional neuroprotective pathway. This is early but credible evidence that GLP-1s could become a meaningful tool in cognitive and neurological aging — worth watching closely as larger trials are designed.
Read more →Alzheimer's Amyloid Drugs Clear Plaques — But Patients Barely Notice the Difference
A major review has found that while lecanemab and donanemab successfully reduce amyloid plaques in the brain, improvements to memory and daily function are too small for most patients to perceive. This directly challenges the narrative that plaque removal equals meaningful disease modification — and raises serious questions about whether these high-cost, high-risk drugs deliver on their promise. For patients and families weighing these options, 'statistically significant' and 'clinically meaningful' are not the same thing.
Read more →Supplements & Compounds
The NIA's Gold-Standard Test Just Failed 11 More Anti-Aging Compounds
The National Institute on Aging's Interventions Testing Program (ITP) — the most rigorous anti-aging supplement trial in existence, using thousands of mice across multiple sites — found that another eleven compounds previously hyped for longevity effects do not extend lifespan. This is a consistent pattern: the ITP has now failed dozens of substances that looked promising in smaller or single-lab studies. Before adding anything new to your stack, the ITP result is the bar every compound needs to clear.
Read more →Research & Papers
Your Mouth Bacteria Predict Biological Age — and Mortality Risk
Researchers analyzed oral microbiome data from nearly 6,000 people across two large NHANES cohorts and built a machine learning model that predicts chronological age from 64 age-dependent bacterial genera. The resulting Oral Microbiome Aging Acceleration (OMAA) score independently predicted all-cause mortality (HR=1.05), frailty, kidney decline, cancer risk (AUC improved from 0.67→0.70), and heart attack risk (AUC 0.76→0.79) — all beyond conventional risk factors. If validated clinically, a simple saliva test could become one of the cheapest, most informative longevity assessments available.
Read more →Rapamycin + Exercise in Older Adults: First Randomized Trial Results Are In
RAPA-EX-01, a randomized double-blind placebo-controlled trial, tested whether 6mg weekly sirolimus (rapamycin) enhances or interferes with functional gains from home-based exercise in 40 sedentary adults aged 65–85 (mean age 72.2). This is one of the first controlled human trials to probe whether rapamycin's mTOR-inhibiting effects complement or cancel exercise adaptation in older adults — a key question for anyone considering both interventions simultaneously. Note: this is a small exploratory trial (n=40) and results should be interpreted accordingly pending larger replication.
Read more →Blocking the Hunger Hormone's Receptor May Strengthen Aging Muscles
In Aging Cell, researchers found that suppressing the ghrelin receptor — best known for stimulating appetite — significantly improved muscle function and countered sarcopenia in older mice. The finding adds ghrelin signaling to the growing list of metabolic pathways with potential relevance to muscle aging and opens a new avenue for sarcopenia drug development. This is a mouse study, so human translation remains uncertain, but ghrelin receptor antagonists are already being investigated in other contexts, which may accelerate the path to clinical trials.
Read more →Lifestyle & Nutrition
150 Minutes of Weekly Aerobic Exercise Lowers Cortisol and Measurably Slows Brain Aging
A first-of-its-kind one-year clinical trial found that 150 minutes of weekly aerobic exercise — exactly the amount in standard public health guidelines — significantly reduced long-term cortisol levels and slowed markers of brain aging. The mechanism appears to run through chronic stress biology: sustained exercise essentially rewires the cortisol response, reducing the neuroinflammatory burden that accumulates over time. This is among the strongest human trial data yet linking a specific, achievable exercise dose directly to brain aging outcomes.
Read more →What the World's Top Aging Scientists Actually Eat — and What They Skip
A science journalist surveyed leading aging researchers on their personal dietary practices, finding a striking consensus around omega-3 fatty acids as the supplement with the strongest evidence base — obtainable cheaply through oily fish or basic supplements. Many experts expressed skepticism about popular longevity supplements like metformin, rapamycin, and NAD+ precursors, noting that human evidence remains limited. For readers overwhelmed by supplement marketing, this piece offers a grounding reality check from the people who study aging for a living.
Read more →Industry & Policy
FDA Peptide Reclassification 2026: What It Means — and What It Doesn't
In late 2023, the FDA moved 19 widely used peptides — including many popular in longevity and performance circles — to its Category 2 list, effectively barring compounding pharmacies from preparing them. Proposed reclassification in 2026 could restore some access, but this piece flags an important caveat: reclassification is not the same as FDA approval, and how you source these therapies still matters enormously. Anyone relying on compounded peptides — or hoping to regain access — should understand the difference between regulatory categories before assuming the path is clear.
Read more →